Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.49 CAD | +3.41% | +4.18% | -11.65% |
06-07 | Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call | |
05-28 | HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.65% | 81.25M | |
+29.04% | 78.4B | |
+0.44% | 25.12B | |
+14.70% | 8.62B | |
+2.20% | 8.55B | |
-28.87% | 6.91B | |
+16.06% | 5.34B | |
+1.58% | 4.17B | |
-8.90% | 3.82B | |
-7.62% | 3.37B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Buy Rating Reiterated at Stifel GMP as Vascepa Prescriptions Rise; Price Target Kept at C$26.00